1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Caliway Biopharmaceuticals Co. L

Caliway Biopharmaceuticals Co. L

6919.TW
Caliway Biopharmaceuticals Co. LTW flagTaiwan Stock Exchange
110.00
TWD
+10.00
- -
171.20BMarket Cap

Total Valuation

Caliway Biopharmaceuticals Co. L carries a market capitalization of 171.20B, placing it among publicly traded companies globally. Its enterprise value stands at 234.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap171.20B
Enterprise Value234.77B

Share Statistics

Caliway Biopharmaceuticals Co. L currently has 1.55B shares outstanding.

Shares Outstanding1.55B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 6,299.75, and the price-to-book ratio stands at 279.61.

PE RatioN/A
PS Ratio6,299.75
PB Ratio279.61
P/TBV Ratio25.46
P/FCF Ratio-586.22
P/OCF Ratio-562.63

Enterprise Valuation

EV / Sales6,172.05
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Caliway Biopharmaceuticals Co. L maintains a current ratio of 109.71, meaning it holds 109.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.03, indicating conservative leverage, while an interest coverage ratio of -4,533.49 demonstrates limited ability to service its debt obligations.

Current Ratio109.71
Quick Ratio106.83
Debt / Equity0.03
Debt / EBITDA0.00
Interest Coverage-4,533.49

Financial Efficiency

Return on Equity (ROE)-44.83
Return on Assets (ROA)-3.66
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)-44.36
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover4.01

Stock Price Statistics

Caliway Biopharmaceuticals Co. L's stock has declined approximately -11.29032% over the past 52 weeks. The 50-day moving average sits at 99.68, while the 200-day moving average is 135.97.

Beta (5Y)N/A
52-Week Price Change-11.29032%
50-Day Moving Average99.68
200-Day Moving Average135.97
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Caliway Biopharmaceuticals Co. L generated 38.04M in revenue and converted that into -351.92M in net income, yielding earnings per share of -0.23. EBITDA reached -707.22M, while operating income came in at -707.22M.

Revenue38.04M
Gross Profit26.52M
Operating Income-707.22M
Pretax Income-351.92M
Net Income-351.92M
EBITDA-707.22M
EBIT-707.22M
Earnings Per Share (EPS)-0.23

Balance Sheet

Caliway Biopharmaceuticals Co. L holds 4.86B in cash and equivalents against 3.00M in total debt, resulting in a net debt position of -784.44M. Total book value stands at 856.98M, with working capital of 4.95B providing operational flexibility.

Cash & Cash Equivalents4.86B
Total Debt3.00M
Net Debt-784.44M
Equity (Book Value)856.98M
Book Value Per Share0.55
Working Capital4.95B

Cash Flow

Caliway Biopharmaceuticals Co. L produced -425.90M in operating cash flow over the past twelve months. After subtracting -17.14M in capital expenditures, free cash flow totaled -443.04M - equivalent to -0.29 per share.

Operating Cash Flow-425.90M
Capital Expenditures-17.14M
Free Cash Flow-443.04M
FCF Per Share-0.29

Margins

Caliway Biopharmaceuticals Co. L operates with a gross margin of 69.72, reflecting its pricing power and cost economics. The operating margin of -1,859.31 and net profit margin of -925.20 provide insight into operational efficiency.

Gross Margin69.72
Operating Margin-1,859.31
Pretax Margin-925.20
Profit Margin-925.20
EBITDA Margin-1,859.31

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.05
FCF Yield-0.17

Stock Splits

Caliway Biopharmaceuticals Co. L's most recent stock split took place on July 14, 2025 with a 1:10 split ratio.

Last Split Date7/14/2025
Split Ratio1:10

Scores

Caliway Biopharmaceuticals Co. L posts an Altman Z-Score of 2,258.94, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2,258.94